Why Novartis Stock Could Keep Rising: Bullish Drivers Ahead

01. Historical Context

Why the current setup can still support more upside

The bull case for Novartis starts from strength, not distress. At CHF 118.04 on May 15, 2026, the stock was below its 52-week high but still much closer to that high than to its 10-year lows.

The reason the bull case survives a weak quarter is product quality. The drag came from US generic erosion, but priority brands still grew strongly: Kisqali +55% cc, Pluvicto +70%, Kesimpta +26%, Scemblix +79%, and Leqvio +69%. Those are not defensive low-single-digit numbers; they are franchise-strength numbers.

What makes this a real rather than easy bull case is valuation. Investors need to believe that generic erosion is temporary enough for the market to reward the growth franchises again.

Bullish setup for Novartis using current verified datapoints — Upside framework anchored to the latest share price, recent results, and current valuation data.

Novartis framework across investor time horizons

Horizon	What matters now	Current datapoint	What would strengthen the thesis
1-3 months	Execution versus guidance	Q1 2026 net sales were USD 13.1 billion, down 5% at constant currencies, while core EPS was USD 1.99, down 15% at constant currencies.	Management keeps 2026 guidance and brand-level momentum remains intact.
6-18 months	Valuation versus revisions	MarketScreener showed Novartis at about 19.2x trailing 2025 earnings, 20.1x 2026 estimated earnings, and 17.3x 2027 estimated earnings. Consensus EPS on MarketScreener was USD 7.244 for 2026 and USD 8.433 for 2027, implying roughly 16.4% growth into 2027.	Consensus EPS moves higher while the multiple does not need to do all the work.
To 2030	Structural compounding	10-year price range CHF 39.77 to CHF 126.65; 10-year CAGR 10.0%.	The company sustains growth through launches, pipeline conversion, and disciplined capital allocation.

02. Key Forces

Five bullish forces that could extend the move

The first bullish driver is priority-brand momentum. Kisqali, Pluvicto, Kesimpta, Scemblix, and Leqvio are still growing fast enough to support a higher earnings base once erosion fades.

The second is the 2025-2030 company algorithm. A stated 5% to 6% sales CAGR gives the market a medium-term reason to stay patient through a softer 2026.

The third is margin quality. FY 2025's 40.1% core operating margin shows the underlying engine is still highly profitable.

The fourth is infrastructure support. The USD 23 billion US manufacturing and R&D program adds tangible capacity behind radioligand therapy, RNA, and other growth platforms.

The fifth is capital return. Novartis is still buying back stock even while investing heavily, which supports long-term per-share growth.

Current factor scorecard for Novartis

Factor	Current Assessment	Bias	Why it matters now
Priority brands	All five major growth brands posted double-digit cc growth in Q1 2026	Bullish	The portfolio still has real internal momentum.
Long-term guide	5%-6% sales CAGR through 2030	Bullish	This supports the medium-term upside case.
Margin base	40.1% core operating margin in FY 2025	Bullish	The business has room to absorb temporary noise.
Valuation	About 20.1x 2026 EPS	Neutral	The upside case needs earnings follow-through.
Erosion cycle	Still hurting Q1 2026 reported growth	Neutral to Bearish	The bull case improves once this fades.

03. Countercase

What could interrupt the rally

The bullish setup is vulnerable if generic erosion remains the dominant narrative for longer than management expects.

It is also vulnerable if the stock stays expensive enough to cap upside. A quality business can still tread water when the multiple already implies confidence.

Finally, the sector backdrop still matters. FactSet shows healthcare lagging on earnings breadth, which makes investors faster to punish any disappointment.

Current threats to the bullish thesis

Risk	Latest datapoint	Current assessment	Bias
Generic erosion	Q1 2026 sales down 5% cc	Main near-term drag	Bearish
Valuation cap	Around 20x 2026 EPS	Upside must be earned	Neutral
Sector breadth	Healthcare still weak in FactSet's Q1 2026 lens	External drag	Neutral
Execution bar	Consensus only Hold on MarketScreener	Market wants proof	Neutral

04. Institutional Lens

What professional research implies for the upside case

The bullish institutional case for Novartis is less about cheapness and more about quality. J.P. Morgan's sector work says healthcare is historically discounted relative to the S&P 500, while Novartis itself has a credible 5% to 6% sales CAGR target through 2030.

FactSet's breadth work is the balancing factor. It says investors are still skeptical about healthcare revisions generally, which is why Novartis needs product strength to keep doing the talking.

That leaves a practical conclusion: Novartis can keep rising, but the cleanest upside path is erosion normalization plus sustained brand growth, not multiple enthusiasm alone.

Named institutional inputs used in this article

Source	Latest update	What it says	Why it matters here
MarketScreener, May 7, 2026	On May 7, 2026, MarketScreener listed 22 analysts on the Novartis ADR with a Hold consensus, average target USD 155.06, low target USD 121.07, and high target USD 178.42.	Analysts see only modest upside on the ADR, which implies the market already gives meaningful credit to quality and capital returns.	That makes execution on priority brands and generic erosion the main swing factors.
IMF, April 2026	Global growth 3.1% in 2026 and 3.2% in 2027.	The IMF said downside risks still dominate because of conflict, fragmentation, and disappointment over AI productivity.	A slower macro tape usually limits multiple expansion for defensive growth names as well as cyclical names.
FactSet, May 1, 2026	Health Care was one of only two S&P 500 sectors reporting a year-over-year earnings decline; the S&P 500 forward P/E was 20.9x.	FactSet's message is that broad equity valuations are not cheap even as healthcare revisions remain mixed.	That raises the bar for stock-specific execution and makes relative valuation important.
J.P. Morgan Asset Management, 2026	Public healthcare multiples sit at 30-year lows relative to the S&P 500 despite USD 318 billion of M&A across 2,500-plus transactions in 2025.	J.P. Morgan's sector view is that policy noise has compressed healthcare valuations relative to the market.	That helps explain why solid pharma execution can still re-rate if policy fears fade.

05. Scenarios

How to trade or own the bullish case with clear triggers

The right way to act on the bull case is to watch whether the market stops looking through the erosion cycle and starts focusing again on the growth franchises.

The key dates are the next quarterly results, the next full-year guide, and whether consensus 2027 EPS keeps moving above the current USD 8.433 estimate.

Bullish scenario map for Novartis

Scenario	Probability	Target range	Trigger	When to review
Fast bull	25%	CHF 135 to CHF 145	The market quickly looks through erosion and refocuses on the growth portfolio.	Review after Q2 2026.
Measured bull	45%	CHF 123 to CHF 134	The stock grinds higher as normalization becomes visible but not fully complete.	Review after FY 2026.
Bull case invalidated	30%	Below CHF 118	Erosion and margin pressure keep dominating the story.	Review if guidance is cut or brand growth slows materially.